Retrospective Study Of The Influence Of Age At Start Of Growth Hormone Treatment On Height Gain In Children Born Small for Gestational Age
- Registration Number
- NCT01897753
- Lead Sponsor
- Pfizer
- Brief Summary
The purpose of this protocol is to retrospectively study the influence of age at start of growth hormone (GH) treatment on height gain in children born small for gestational age (SGA).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 264
-
SGA children.
- Treated with GH at least 36 months.
- Patients treated with GH for other indications (not SGA).
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Small For Gestational Age (SGA) Children growth hormone SGA children under growth hormone treatment for more than 36 months.
- Primary Outcome Measures
Name Time Method height SDS 36 months height SDS of SGA children after 36 months of treatment
- Secondary Outcome Measures
Name Time Method height increase 36 months Change from Baseline in Lipid Parameters at Month X 36 months Mean Total Cholesterol (TC), Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), and Triglyceride blood concentrations.
Trial Locations
- Locations (12)
H. Germans Trias i Pujol
🇪🇸Badalona, Barcelona, Spain
H. Sant Joan de Déu
🇪🇸Esplugues de Llobregat, Barcelona, Spain
H.Marqués de Valdecilla
🇪🇸Santander, Cantabria, Spain
Hospital Virgen de la Arrixaca
🇪🇸El Palmar, Murcia, Spain
Hospital Virgen del Camino
🇪🇸Pamplona, Navarra, Spain
Capio H.Universitario Sagrat Cor
🇪🇸Barcelona, Spain
H. Vall d'Hebron
🇪🇸Barcelona, Spain
H.Gregorio Marañón
🇪🇸Madrid, Spain
Hospital La Paz
🇪🇸Madrid, Spain
Hospital Carlos Haya
🇪🇸Málaga, Spain
Scroll for more (2 remaining)H. Germans Trias i Pujol🇪🇸Badalona, Barcelona, Spain